TerminatedPhase 3NCT02353949

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Studying Frontotemporal dementia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Zurich
Principal Investigator
Christoph Hock, MD, Prof.
University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy
Intervention
Flutemetamol (Vizamyl)(drug)
Enrollment
11 target
Eligibility
All sexes
Timeline
20152019

Study locations (1)

Collaborators

ETH Zurich

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02353949 on ClinicalTrials.gov

Other trials for Frontotemporal dementia

Additional recruiting or active studies for the same condition.

See all trials for Frontotemporal dementia

← Back to all trials